Modulation of immunologic interactions in breast cancer tissue

Speaker: Sibylle Loibl

S. Loibl compares immunogenic capacities of HER2-positive and triple-negative breast cancer (TNBC) with some other tumour types. She explores the tumour infiltrating lymphocytes from a marker’s perspective, as well as relations with a response to therapy. In addition, she explains the results of early studies that tested immune checkpoint inhibitors in patients with metastatic TNBC.

Discussion Points

  • Clinical relevance of immunologic parameters
  • Checkpoint inhibitors in metastatic triple-negative breast cancer